GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Immunic Inc (NAS:IMUX) » Definitions » Shareholder Yield %

Immunic (Immunic) Shareholder Yield % : -0.51% (As of Dec. 2023)


View and export this data going back to 2014. Start your Free Trial

What is Immunic Shareholder Yield %?

Shareholder Yield % is how much money shareholders receive from a company that is in the form of cash dividends, net stock repurchases, and debt reduction. It is a measure of shareholder return. As of today, Immunic's Shareholder Yield % was -0.51%.


Immunic Shareholder Yield % Historical Data

The historical data trend for Immunic's Shareholder Yield % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Immunic Shareholder Yield % Chart

Immunic Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Shareholder Yield %
Get a 7-Day Free Trial Premium Member Only Premium Member Only -18.79 -10.09 -0.14 0.01 -0.84

Immunic Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
Shareholder Yield % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.01 -0.55 -0.63 -1.17 -0.84

Competitive Comparison of Immunic's Shareholder Yield %

For the Biotechnology subindustry, Immunic's Shareholder Yield %, along with its competitors' market caps and Shareholder Yield % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Immunic's Shareholder Yield % Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Immunic's Shareholder Yield % distribution charts can be found below:

* The bar in red indicates where Immunic's Shareholder Yield % falls into.



Immunic Shareholder Yield % Calculation

Immunic's Shareholder Yield % for the quarter that ended in Dec. 2023 is calculated as:

Shareholder Yield %=Dividend Yield %+Buyback Yield %+Net Debt Paydown Yield %
=0 %+0 %+-0.84 %
=-0.84 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* All the data are calculated by TTM values. Note that if a companies is traded in several exchanges, then we calculate the company level data for Shareholder Yield % using the primary share class stock data. The calculation result in definition page is for demonstration purpose only, and it's showing the share class level data. Therefore, the numbers in the calculation may differ from elsewhere if the stock is not a primary share.


Immunic  (NAS:IMUX) Shareholder Yield % Explanation

Shareholder Yield % is how much money shareholders receive from a company that is in the form of cash dividends, net stock repurchases, and debt reduction. The term was coined by William W. Priest of Epoch Investment Partners in a paper in 2005 entitled The Case for Shareholder Yield as a Dominant Driver of Future Equity Returns. William Priest indicated that "shareholder yield is a term that we came up with to reflect the various ways dividends can be paid to owners of a business in a publicly-traded company."

Shareholder Yield % is calculated by three components: Dividend Yield %, Buyback Yield %, and Net Debt Paydown Yield %.

Dividend Yield % shows how much a company pays out in dividends each year relative to its stock price, which is most obvious form of shareholder return.

Buyback Yield % is the net repurchase of shares outstanding over the market capital of the company. Shares repurchases also increase shareholder value by returning the money back to shareholders.

Net Debt Paydown Yield % is the change in average of four quarters of company's total debt over a company's market cap. Assuming the total value of a company remains that same, shareholder value is increased as debt is reduced.


Immunic Shareholder Yield % Related Terms

Thank you for viewing the detailed overview of Immunic's Shareholder Yield % provided by GuruFocus.com. Please click on the following links to see related term pages.


Immunic (Immunic) Business Description

Traded in Other Exchanges
Address
1200 Avenue of the Americas, Suite 200, New York, NY, USA, 10036
Immunic Inc is a clinical-stage biopharmaceutical company developing a pipeline of selective oral immunology therapies aimed at treating chronic inflammatory and autoimmune diseases, including ulcerative colitis, Crohn's disease, relapsing-remitting multiple sclerosis, and psoriasis. The company is developing three small molecule products, which include IMU-838, which is a selective immune modulator that inhibits the intracellular metabolism of activated immune cells by blocking the enzyme DHODH; IMU-935 is an inverse agonist of RORyt, and IMU-856 targets the restoration of the intestinal barrier function.
Executives
Glenn Whaley officer: PAO and Controller C/O PERNIX THERAPEUTICS HOLDINGS, INC., 10 NORTH PARK PLACE, SUITE 201, MORRISTOWN NJ 07960
Richard Alan Rudick director 1200 AVENUE OF THE AMERICAS, SUITE 200, NEW YORK NY 10036
Joerg Neermann director IMMUNIC AG, AM KLOPFERSPITZ 19, MARTINSRIED 2M 82152
Daniel Vitt director, officer: CEO, President IMMUNIC AG, AM KLOPFERSPITZ 19, MARTINSRIED 2M 82152
Monika Maria Toernsen director ONE COMMERCE SQUARE, 2005 MARKET STREET, 39TH FLOOR, PHILADELPHIA PA 19103
Duane Nash director C/O VITAL THERAPIES, INC., 15010 AVENUE OF SCIENCE, SUITE 200, SAN DIEGO CA 92128
Andreas Muehler officer: Chief Medical Officer 1200 AVENUE OF THE AMERICAS, SUITE 200, NEW YORK CITY NY 10036
Manfred Groeppel officer: Chief Operating Officer IMMUNIC AG, AM KLOPFERSPITZ 19, MARTINSRIED 2M 82152
Barclay A Phillips director C/O CANCER VAX CORP, 2110 RUTHERFORD ROAD, CARLSBAD CA 92008
Tamar D Howson director
Sanjay S Patel officer: Chief Financial Officer 10 N. PARK PLACE, SUITE 201, MORRISTOWN NJ 07960
Claudio Nessi 10 percent owner C/O NEOMED, 7 PLACE DU MOLARD, 1204 GENEVA V8 1204
Anne-mari Paster 10 percent owner C/O OMEGA FUND MANAGEMENT, LLC, 888 BOYLSTON ST., SUITE 1111, BOSTON MA 02199
Omega Fund V Gp, L.p. 10 percent owner 888 BOYLSTON ST., SUITE 1111, BOSTON MA 02199
Lsp V Cooperatieve U.a. 10 percent owner JOHANNES VERMEERPLEIN 9, AMSTERDAM P7 1071 DV